Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?

Pfizer expects 2026 revenue of $60.5-$62.5 billion, below 2025's $62.6 billion, and adjusted EPS of $2.80-$3.00 versus $3.22 in 2025, as lower COVID product sales and patent expirations weigh on results. The company estimates its loss-of-exclusivity cliff will reduce 2026 revenue by approximately $1.1 billion, affecting products including Eliquis, Ibrance, Xeljanz and Xtandi. Pfizer is relying on double-digit growth in recently launched and acquired products, including Metsera obesity programs and 3SBio oncology assets, to support a return to growth from 2029; consensus 2026 EPS has edged up to $2.98 from $2.96.

Analysis

PFE's low multiple is not automatically a margin of safety: the market is likely valuing a sequence of replacement-risk events rather than a single 2026 earnings trough. Acquired obesity and oncology assets add execution, integration and potential impairment risk before they contribute material revenue, while patent erosion has unusually high operating leverage because commercial infrastructure cannot be reduced dollar-for-dollar without compromising launches. Over the next 1-3 months, the key issue is whether management can hold consensus through the next earnings update; another reduction in the COVID base or launch trajectory would likely matter more than the modestly improved EPS estimates.

Competitive read-through favors AZN and JNJ over PFE. Their oncology franchises have enough breadth and established prescriber relationships to absorb share in adjacent indications, whereas PFE must spend heavily to establish differentiated positions in crowded PD-(L)1/VEGF and obesity markets. MRK is a more nuanced beneficiary: its Keytruda concentration creates its own medium-term exclusivity problem, but near-term oncology cash flow and trial infrastructure make it a stronger partner or acquirer than PFE.

The contrarian case is that PFE's valuation already discounts a prolonged trough and that non-COVID growth plus cost actions can stabilize free cash flow sooner than headline revenue implies. That requires independently verifiable launch-market-share data and disciplined deal spending; a high-single-digit post-2028 growth objective should receive little multiple credit today because it lies beyond several patent and clinical milestones. Structural upside over 6-18 months exists only if new-product revenue begins offsetting erosion earlier than modeled, not merely growing at a high percentage from a small base.

Key Decisions for Investors

• Maintain an underweight PFE versus XLV for the next 1-3 months; reassess only if quarterly new-product sales plus operational non-COVID growth exceed estimated LOE and COVID declines for two consecutive quarters. Thesis is falsified by sustained guidance support and evidence of earlier-than-expected replacement revenue.
• Pair trade: long AZN / short PFE, sized beta-neutral, over 6-12 months. AZN offers diversified oncology compounding while PFE faces negative operating leverage and execution-dependent replacement growth; target a 10-15% relative return, with a stop if AZN oncology growth decelerates below low double digits or PFE materially raises 2027-28 revenue expectations.
• Prefer JNJ over PFE for defensive healthcare exposure through the next earnings cycle. JNJ's broader earnings base reduces binary launch risk; use any PFE rally driven solely by the headline forward P/E discount to add to the relative short rather than initiating an outright PFE value long.
• Do not underwrite MTSR-related upside into PFE until transaction terms, closing risk, development timelines and commercialization economics are fully disclosed. Monitor for deal-related dilution beyond guidance or obesity trial setbacks as catalysts for renewed PFE estimate cuts.